Huangshi Hygienic Material Medicine released U.S. drugs without identity and strength testing and lacked stability data for labeled expiration dates.
What happened
FDA inspected the facility from August 26 to 30, 2024, and found that the firm had not performed identity and strength testing of active ingredients before releasing multiple batches for the U.S. market. FDA also found that U.S. product expiration dates were based on stability testing of domestic China products even though the U.S. formulations differed. FDA reviewed the firm’s September 20, 2024 response and found it inadequate.
What FDA found
The firm released drug batches for the U.S. market without testing each batch for identity and strength of active ingredients against final specifications.
21 CFR 211.165(a)The firm assigned expiration dates to U.S. products using stability testing for different domestic products, without stability data supporting those U.S. formulations.
21 CFR 211.137(a)
What FDA wants
FDA tells the company to correct the violations promptly and respond in writing within 15 working days with a corrective action plan, including full testing of retain samples, a remediated stability program, interim measures for products already in the U.S. market, and an independent assessment of test methods. FDA also recommends engaging a qualified CGMP consultant if the firm intends to resume U.S. manufacturing.
Who should pay attention
- U.S. distributors and retailers selling imported OTC drugs
- companies buying finished drug products from this manufacturer
- quality teams overseeing imported drug suppliers
This is a summary. Read the original letter on fda.gov.